as 10-07-2025 3:28pm EST
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Founded: | 1996 | Country: | United States |
Employees: | N/A | City: | NOVATO |
Market Cap: | 11.1B | IPO Year: | 1999 |
Target Price: | $92.21 | AVG Volume (30 days): | 2.2M |
Analyst Decision: | Buy | Number of Analysts: | 20 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 3.40 | EPS Growth: | 154.69 |
52 Week Low/High: | $52.48 - $73.51 | Next Earning Date: | 10-28-2025 |
Revenue: | $3,063,608,000 | Revenue Growth: | 18.36% |
Revenue Growth (this year): | 13.35% | Revenue Growth (next year): | 9.18% |
BMRN Breaking Stock News: Dive into BMRN Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Insider Monkey
6 days ago
Insider Monkey
6 days ago
Zacks
7 days ago
Zacks
19 days ago
Simply Wall St.
21 days ago
Insider Monkey
21 days ago
Insider Monkey
22 days ago
The information presented on this page, "BMRN BioMarin Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.